Viiv Healthcare

This Phase 3 trial tests whether people with HIV who are already well-controlled on daily pills can switch to a monthly injection of two drugs (cabotegravir and rilpivirine) and stay just as healthy. About 630 adults whose virus is suppressed on a standard three-drug pill regimen…

This study tests a new drug, VH3810109, given with another HIV medicine (cabotegravir) in adults whose HIV is already well-controlled. The goal is to see if this combination can keep the virus suppressed as well as standard treatments. About 185 participants will receive either t…

This study tests a long-acting injectable HIV medication (CAB LA + RPV LA) in people whose virus is still detectable despite taking daily oral pills. About 332 participants will either get the shots or continue standard oral therapy. The goal is to see if the injections can bette…

This Phase 3 trial tests whether switching from daily HIV pills to monthly injections of cabotegravir and rilpivirine can keep the virus suppressed in adults with HIV. About 618 participants who are already virally suppressed will either stay on their current pills or switch to t…

This early-stage study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the hidden viral reservoir in people living with HIV. About 107 adults, either new to treatment or already on stable therapy,…

This study tests whether a simpler two-drug pill (dolutegravir/lamivudine) works as well as a standard three-drug pill (bictegravir/emtricitabine/tenofovir alafenamide) for adults with HIV who have never been treated. About 473 participants will take one of the two pills daily fo…

This early-stage study tests a new lab-made antibody called VH4527079 in healthy adults and people with HIV. The goal is to check if it is safe and how the body processes it when given as a single shot or multiple infusions. About 102 participants aged 18-55 will take part. This …

This study tests a new HIV medicine, fostemsavir, in people whose HIV has become resistant to many other drugs. About 371 adults with multi-drug resistant HIV took part. The goal was to see if fostemsavir could lower the amount of virus in their blood. This is a disease control s…

This study is checking the long-term safety and effectiveness of a long-acting injectable drug called cabotegravir (CAB LA) for preventing HIV. It includes about 3,500 people who already received CAB LA in earlier HIV prevention studies. Participants will continue getting the sho…

This study tests a new version of the HIV prevention drug cabotegravir given as a shot every 4 months. About 229 teens and adults at risk for HIV will receive the injection to see how well the drug stays in the body and if it is safe. The goal is to make HIV prevention easier by …

This study involves 65 healthy adults without HIV to see how well they tolerate two long-acting injections (cabotegravir and lenacapavir). Participants will receive both shots at different times and report on pain, bother, and overall satisfaction. The goal is to understand injec…